Brand VerifiedFrance

Virbac S.A.

Virbac

Virbac is a dedicated animal health pharmaceutical company founded by a veterinarian in 1968, operating on the principle "by a veterinarian, for veterinarians." Headquartered in Carros, Provence-Alpes-Côte d'Azur, France, Virbac generated EUR 1.465 billion (~USD 1.6 billion) in 2025 revenue (organic growth of 7.9%), employing 6,400 employees across 12 production sites in 12 countries. Companion animal products now constitute 62% of total sales, with dental care, dermatology, and specialty endocrine therapeutics (bolstered by the landmark €107.8M Thyronorm acquisition) driving premium pricing in North American and European markets.

Strengths:
• Companion Animal Purity: 62% of revenue from companion animals, with particularly strong positions in dental care (VeggieDent, Enzadent) and dermatology (Cortavance, Allerderm)
• Strategic Asia-Pacific Expansion: €280M acquisition of Japanese animal health company Sasaeah in 2025 added manufacturing facilities in Japan and Vietnam, instantly establishing APAC production base
• Regional Manufacturing Autonomy: 12 production sites across 12 countries, including a recently initiated viral antigen manufacturing plant in Montevideo, Uruguay—the first of its kind in Latin America
• Veterinarian-Centric Heritage: Founded by a veterinarian, the company maintains deep clinical credibility and loyalty within the global veterinary community
• Capital Discipline: €102M in 2025 capital expenditure focused on solving supply chain bottlenecks and supporting future volume growth in premium therapeutic categories
Weaknesses:
• Currency Exposure: Significant revenue from Latin America, Asia-Pacific, and Middle East/Africa creates recurring currency translation headwinds (noted in 2025 results)
• Mid-Tier Revenue Scale: At ~$1.6B, Virbac operates in a competitive middle tier where R&D budgets are materially smaller than the Big Four, constraining pipeline breadth
• Integration Risk: The recent Sasaeah acquisition introduces operational complexity across Japanese, Vietnamese, and existing French manufacturing sites requiring multi-year integration efforts

Business Nature

Virbac is a dedicated animal health pharmaceutical company founded by a veterinarian in 1968, operating on the principle "by a veterinarian, for veterinarians." The company's industrial footprint spans 12 manufacturing sites across 12 countries, strategically distributed to ensure regional supply chain resilience. Its Carros, France headquarters houses advanced vaccine and sterile injectable production.

In Latin America, its Montevideo, Uruguay facility has recently broken ground on a dedicated viral antigen manufacturing plant—a landmark investment that gives Virbac rare in-region core vaccine antigen production capability. The company completed its landmark €280 million acquisition of Japanese animal health company Sasaeah in 2025, adding manufacturing facilities in Japan and Vietnam, plus 500+ specialized employees, instantly establishing a significant Asia-Pacific production base. Companion animal products now constitute 62% of total sales.

Core Business Areas

Companion Animal Portfolio — Core Business
• Dental Care: VeggieDent / Enzadent
• Dermatology: Cortavance / Allerderm
• Parasiticides: Effipro / Milbemax
• Endocrinology: Thyronorm post-acquisition
• Vaccines: Canigen / Feligen
• Pet Nutrition

Industry Rankings

7Top 10 Veterinary Pharmaceuticals & Pet Healthcare Companies

Brand

7Top 10 Veterinary Pharmaceuticals & Pet Healthcare Manufacturers & Suppliers

Mfr

Corporate Report

Virbac S.A. is a France-based dedicated animal health pharmaceutical company headquartered in Carros, Provence-Alpes-Côte d'Azur. Founded in 1968 by a veterinarian, the company operates on the principle "by a veterinarian, for veterinarians." In 2025, Virbac generated EUR 1.465 billion (~USD 1.6 billion) in global revenue (7.9% organic growth), employing 6,400 people across 12 production sites in 12 countries, with products sold in over 100 countries.

Core Business

Virbac's companion animal portfolio (62% of total revenue) is characterized by premium positions in dental care (VeggieDent, Enzadent), dermatology (Cortavance, Allerderm), and parasiticides (Effipro, Milbemax). The landmark €107.8M acquisition of Thyronorm in 2025—the leading treatment for feline hyperthyroidism—significantly strengthened its position in the high-growth specialty endocrine therapeutics segment. Its livestock portfolio covers vaccines, anti-infectives, and nutritional products across bovine, porcine, and poultry species.

Global Presence

Operating through 35 wholly-owned subsidiaries and products in 100+ countries, Virbac's 12 manufacturing sites are strategically distributed across France, Uruguay, Brazil, Vietnam, Japan (post-Sasaeah acquisition), and other key regions. The Montevideo, Uruguay facility's new viral antigen plant represents a landmark investment in Latin American vaccine self-sufficiency. The 2025 Sasaeah acquisition (€280M) added significant manufacturing capability in Japan and Vietnam, instantly establishing a competitive Asia-Pacific production footprint serving the world's fastest-growing pet pharmaceutical markets.

Key Strengths

• 62% companion animal revenue concentration with premium positions in dental, dermatology, and endocrine care
• 12-country manufacturing network with landmark Uruguay viral antigen plant investment
• €280M Sasaeah acquisition establishing immediate Asia-Pacific manufacturing presence
• Veterinarian-founded heritage creating deep clinical credibility and community loyalty
• Consistent 7.9% organic growth demonstrating effective commercial execution

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Carros, Provence-Alpes-Côte d'Azur, France

Founded

1968

Employees

6,400

Factories

12 production sites across 12 countries

Listing

Euronext Paris: VIRP

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website Euronext Paris: VIRP , Virbac Corporate Website
Wikipedia — Virbac
Euronext — Virbac (VIRP)

Back to Rankings